Molecular pathology for cholangiocarcinoma:a review of actionable genetic targets and their relevance to adjuvant&neoadjuvant therapy,staging,follow-up,and determination of minimal residual disease
作者机构：Division of Surgical OncologyWinship Cancer InstituteEmory UniversityAtlantaGAUSA
出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)
年 卷 期：2024年第13卷第1期
页 面：29-38页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Cholangiocarcinoma(CCA) biliary tract cancer(BTC) targeted therapy molecular profiling
摘 要：Cholangiocarcinoma(CCA)represents a group of epithelial cell tumors classified based on their anatomic location along the biliary *** rare malignancy is often diagnosed at an advanced stage and deemed *** for those patients who are surgical candidates,recurrence rates are high and survival rates *** mainstay of therapy for advanced CCA remains cisplatin plus gemcitabine,with a median overall survival(mOS)under 12 months,although the TOPAZ-1 trial showed a survival benefit with the addition of programmed cell death ligand 1(PD-L1)*** recent years,molecular profiling has revealed a wealth of potentially targetable genetic alterations,including fibroblast growth factor receptor(FGFR)fusions,isocitrate dehydrogenase 1(IDH1)mutations,human epidermal growth factor receptor 2(HER2)amplification and overexpression,and microsatellite instability(MSI).These discoveries have prompted numerous clinical trials employing drugs against these specific genetic *** foundation laid by early clinical studies and the landscape of ongoing trials are both summarized *** the role of adjuvant therapy has yet to be defined in this disease,we emphasize the importance of employing targeted therapies in trials in the adjuvant and neoadjuvant spaces and discuss ways to overcome challenges due to low incidence of targetable *** medicine for this disease promises significant clinical benefit to patients,but further investigation is needed.
维普期刊数据库